Eric Fossel
Chief Executive Officer Viska Bio
Seminars
Wednesday 18th February 2026
Targeting GBM: Novel Agent, Unique Mechanism
3:00 pm
- Our technology fuses a tumor targeting nanobody to a modified highly active xanthine oxidase enzyme that generates localized production of high levels of reactive oxygen species, triggering immunogenic cell death and promoting immune cell recruitment.
- Our lead program, VISK-103, which targets EGFR, has demonstrated in vitro inhibition of select established and patient-derived GBM cell lines.
- VISK-103 inhibits tumor progression of mouse xenograft models including GBM with no preliminary evidence of toxicity.
